FEATURES OF ANTIGEN-ANTIBODY INTERACTION DURING USE OF LINEAR SYNTHETIC PEPTIDES AND MULTIPEPTIDE ANTIGEN MODELING ANTIGENIC DETERMINANTS OF HEPATITIS A VIRUS


Cite item

Full Text

Abstract

Aim. To study features of antigen-antibody interaction during use of linear synthetic peptides and multipeptide antigen modelling antigenic determinants of hepatitis A virus (HAV) and to evaluate perspectives for use of heterogeneous tetrameric multipeptide antigens for detection of HAV serological markers. Materials and methods. Linear peptides VP1 and VP3 were synthesized by fluorenylmethyloxycarbonyl (Fmoc)-polyamide solid phase method. MAP 4(VP1+VP3) was synthesized according to 9-Fmoc strategy. Interaction of these peptides with anti-HAV IgM positive sera from patients with HA was studied by noncompetitive and competitive methods of immunoenzyme assay. Results. Using immunoenzyme assay, high heterogeneity of immune response in patients with HA (62 and 67% in two groups) was shown. MAP 4 (VP1+VP3), unlike the combination of linear peptides VP1 and VP3, interacted with anti-HAV IgM in 41 — 45% of sera and, at the same time, did not lead to false positive results. Conclusion. Population of HAV is not so uniform which is usually assumed. It could be reasonable to use heterogenous multipeptide antigens, including those containing VP1 (11 — 25 a.r.) and VP3 (110 — 121 a.r.), for the development of new assays for HA diagnostics.

Full Text

ОСОБЕННОСТИ ВЗАИМОДЕЙСТВИЯ АНТИГЕН-АНТИТЕЛО ПРИ ИСПОЛЬЗОВАНИИ ЛИНЕЙНЫХ СИНТЕТИЧЕСКИХ ПЕПТИДОВ И МУЛЬТИПЕПТИДНОГО АНТИГЕНА, МОДЕЛИРУЮЩИХ АНТИГЕННЫЕ ДЕТЕРМИНАНТЫ ВИРУСА ГЕПАТИТА А
×

About the authors

I. V Kruglov

Mechnikov Research Institute of Vaccines and Sera; Ivanovsky Institute of Virology, Moscow; Department of Peptide and Protein Chemistry, CID-CSIC, Barcelona, Spain

T. V Simonova

Mechnikov Research Institute of Vaccines and Sera; Ivanovsky Institute of Virology, Moscow; Department of Peptide and Protein Chemistry, CID-CSIC, Barcelona, Spain

J. A Perez

Mechnikov Research Institute of Vaccines and Sera; Ivanovsky Institute of Virology, Moscow; Department of Peptide and Protein Chemistry, CID-CSIC, Barcelona, Spain

I. Haro

Mechnikov Research Institute of Vaccines and Sera; Ivanovsky Institute of Virology, Moscow; Department of Peptide and Protein Chemistry, CID-CSIC, Barcelona, Spain

References

  1. Emini E.A., Hughes J.V., Perlow D.S. et al. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J. Virol. 1985, 55: 836—839.
  2. Haro I., Pinto R.M., Gonzalez-Dankaart J.F. et al. Anti-hepatitis A virus antibody response in mice elicited by different forms of a synthetic VP1 peptide. Microbiol. Immunol. 1995, 39: 485—490.
  3. Hughes J.V., Stanton L.W., Tomassini J.E. et al. Neutralizing monoclonal antibodies to HAV: partial localization of a neutralizing antigenic site. J. Virol. 1984, 52: 465—473.
  4. Lemon S.M., Barclay W., Ferguson M. et al. Immunogenicity and antigenicity of chimeric picornaviruses which express HAV peptide sequences: evidence for a neutralization domain near the amino terminus of VP1 of HAV. Virology, 1992, 188 (1): 285—295.
  5. Lemon S.M., Ping L.H. In: B.L.Semler, E. Ehrenfeld (ed.). Molecular aspects of picornavirus infection and detection. 1989, p. 193—208.
  6. Mattoli S., Imberti L., Stellini R. et al. Mimicry of the immunodominant conformation-dependent antigenic site of HAV by motifs selected from synthetic peptide libraries. J. Virol. 1995, 69: 5294—5299.
  7. Nainan O.V., Brinton M.A., Margolis H.S. Identification of amino acids located in the antibody binding sites of human HAV. Virology. 1992, 191: 984—987.
  8. Nardin E.H., Oliveira G.A., Calvo-Calle J.M. et al. The use of MAPs in the analysis and induction of protective immune responses against infectious diseases. Adv. Immunol. 1995, 60: 105—149.
  9. Perez J.A., Gonzalez-Dankaart J.F., Reig F. et al. Solid phase synthesis and immunogenicity of a VP3 peptide from HAV. Biomed. Peptid. Prot. Nucl. Acids. 1995, 1: 93—100.
  10. Ping L.H., Jansen R.W., Stapleton J.T. et al. Identification of an immunodominant antigenic site involving the capsid protein VP3 of HAV. PNAS USA. 1988, 85: 8281—8285.
  11. Ping L.H., Lemon S.M. Antigenic structure of human HAV defined by analysis of escape mutants selected against murine monoclonal antibodies. J. Virol. 1992, 66: 2208—2216.
  12. Stapleton J.T., Lemon S.M. Neutralization escape mutants define a dominant immunogenic neutralization site on HAV. Ibid. 1987, 61: 491—498.
  13. Tam J.P. Synthetic peptide vaccine design: syn- thesis and properties of a high-density MAP system. PNAS USA. 1988, 85: 5409—5411.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Kruglov I.V., Simonova T.V., Perez J.A., Haro I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies